Oppenheimer cuts Connect Biopharma price target to $5
Oppenheimer maintained Connect Biopharma at Outperform while cutting its price target to $5.00 per share from $8.00, per Benzinga.
Oppenheimer maintained Connect Biopharma at Outperform while cutting its price target to $5.00 per share from $8.00, per Benzinga.